Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AbbVie Terminates 11-Year Calico Partnership, Shifts Focus to Biologics and Genetic Therapies

AbbVie has announced the end of its long-standing collaboration with Alphabet's Calico Life Sciences, marking a significant shift in the pharmaceutical giant's research and development strategy. The termination of this 11-year partnership, which focused on age-related diseases, will result in the layoff of approximately 100 chemists and a reallocation of resources towards biologics and genetic therapies.

NoahAI News11/14/2025

Alkermes Advances Narcolepsy Drug to Phase III, Positioning for Market Leadership

Alkermes, a prominent player in the pharmaceutical industry, has reported significant progress in its narcolepsy treatment program, setting the stage for a potential market breakthrough. The company's investigational orexin 2 receptor agonist, alixorexton, has demonstrated promising results in mid-stage trials, propelling the drug candidate towards late-stage development.

NoahAI News11/14/2025

Third Arc Bio Partners with Adagene for Novel T Cell Engager Development

Third Arc Bio, a California-based biotech company, has announced a significant partnership with Suzhou-based Adagene to develop two novel T cell engagers targeting unique cancer antigens. This collaboration marks another step in the growing trend of pharmaceutical companies looking to China for innovative assets and partnerships.

NoahAI News11/14/2025

Day One Biopharmaceuticals Acquires Mersana Therapeutics in $285 Million Deal, Expanding ADC Portfolio

Day One Biopharmaceuticals has announced the acquisition of Mersana Therapeutics in a deal valued at up to $285 million, significantly bolstering its antibody-drug conjugate (ADC) pipeline. The agreement, which comes after Mersana's strategic restructuring earlier this year, centers around the promising B7-H4-targeted ADC, emiltatug ledadotin (Emi-Le).

NoahAI News11/14/2025

FDA Approves Kura and Kyowa Kirin's Komzifti for Subset of AML Patients

The U.S. Food and Drug Administration (FDA) has granted approval to Komzifti (ziftomenib), a new oral medication developed by Kura Oncology and Kyowa Kirin for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible nucleophosmin 1 (NPM1) mutation. This approval marks a significant milestone in the treatment of AML, a disease where specific options for patients with NPM1 mutations have been historically limited.

NoahAI News11/14/2025

Korro Bio's RNA Editing Setback Leads to Strategic Shift and Layoffs

Korro Bio, a leader in the RNA editing field, has announced a significant change in direction following disappointing results from its lead program for alpha-1 antitrypsin deficiency (AATD). The company's shares plummeted 80% as it revealed plans to abandon its primary treatment, restructure its workforce, and pursue a new research strategy.

NoahAI News11/14/2025

Siemens to Reduce Stake in Siemens Healthineers, Marking Shift in Corporate Strategy

Siemens, the German industrial conglomerate, has announced plans to significantly reduce its stake in Siemens Healthineers, its medical technology subsidiary. This strategic move marks a pivotal moment for both companies as they seek to refine their focus and accelerate growth in their respective sectors.

NoahAI News11/14/2025

Pharmaceutical Companies Refocus Clinical Pipelines Amid Financial Constraints

In a series of strategic moves aimed at conserving cash and optimizing resources, three prominent biotech companies—Century Therapeutics, Candel Therapeutics, and MacroGenics—have announced significant changes to their clinical pipelines. These decisions, disclosed in their respective third-quarter earnings releases, reflect the ongoing challenges faced by pharmaceutical firms in balancing innovative research with financial sustainability.

NoahAI News11/14/2025

Third Arc Bio and Adagene Forge $840M Deal for Innovative T-Cell Engager Technology

In a significant move that promises to advance the development of precision cancer therapies, Third Arc Bio has entered into a licensing agreement with Adagene for its cutting-edge Safebody technology. The deal, announced on November 13, 2025, could be worth up to $840 million, highlighting the pharmaceutical industry's growing interest in masked antibody platforms for targeted cancer treatment.

NoahAI News11/14/2025

Zealand Halts Dual GLP-1/GLP-2 Agonist Development Amid Crowded Obesity Treatment Landscape

Zealand Pharma has announced the suspension of development for its dual GLP-1/GLP-2 agonist, dapiglutide, citing an increasingly competitive obesity treatment market. The decision comes as part of the company's strategic effort to reallocate resources towards programs with greater potential for clinical differentiation and long-term value creation.

NoahAI News11/14/2025

Boryung Expands Penicillin Production in South Korea, Addressing Essential Drug Supply

South Korea's Boryung Corporation has broken ground on a significant expansion of its penicillin manufacturing facility in Ansan, South Korea. The project aims to double the capacity of the company's oral penicillin antibiotic production line, responding to government directives and addressing supply chain concerns that arose during the COVID-19 pandemic.

NoahAI News11/14/2025

Gilead's HIV Treatment Breakthrough: Single-Tablet Combo of Bictegravir and Lenacapavir Succeeds in Phase 3 Trial

Gilead Sciences has announced a significant milestone in HIV treatment with the successful phase 3 trial of its investigational single-tablet regimen combining bictegravir and lenacapavir (BIC/LEN). This development represents a potential game-changer for individuals currently managing complex multi-tablet HIV regimens.

NoahAI News11/14/2025

«1...62 63 64...67 »